Classification:
Title:
Rivaroxaban
CAS NO.：
366789-02-8
Summary:
GMP
Description:
Rivaroxaban is an oral anticoagulant that works as a direct factor Xa inhibitor, effectively preventing and treating thromboembolic disorders. It is widely used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and to treat or prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). Rivaroxaban provides predictable pharmacokinetics, rapid onset of action, and does not require routine blood monitoring. Its fixed-dose regimen improves patient compliance and treatment convenience.It is also indicated after hip or knee replacement surgery to prevent venous thromboembolism, offering effective protection and improving recovery outcomes for postoperative patients.
Keywords:
Salcaprozate Sodium（SNAC）
Sodium Decanoate/Sodium Caprate（C10）
Potassium decanoate
N-(5-chlorosalicyloyl)-8-aminocaprylic acid（5-CNAC）（ 1:1 ）、（ 1:2 ）
10-(2-Hydroxybenzamido)decanoic acid (SNAD) (1:1) 、（1:2）
Sodium; 7-(2-hydroxy-benzoylamino)-heptanoate (SNAG)
Similar related products
The products supplied by the company are only used for research and development. Except for the approval of the competent authority, it is strictly prohibited to be used in the production and sales of medicines, food and health products.
NO.
Name
CAS
Abstract
More
